Brief: Pfizer Co & Astellas Announce Final Overall Survival Results From Phase 3 Embark Study For Xtandi In Combination With Leuprolide
19/10/2025 09:15
Oct 19 (Reuters) - Astellas Pharma Inc 4503.T: PFIZER: CO & ASTELLAS ANNOUNCE FINAL OVERALL SURVIVAL RESULTS FROM PHASE 3 EMBARK STUDY FOR XTANDI IN COMBINATION WITH LEUPROLIDE PFIZER: XTANDI PLUS LEUPROLIDE REDUCED RISK OF DEATH BY 40% VERSUS LEUPROLIDE ALONE IN MEN WITH A TYPE OF ADVANCED PROSTATE CANCER Source: https://tinyurl.com/tbbct8sw Further company coverage: 4503.T ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Astellas Pharma
See all newsFocus: Trump's push for the world's lowest drug prices hits snag with mid-sized companies
China detains two Japanese nationals suspected of smuggling banned goods (updated)
Brief: Astellas Pharma: Institutional Shareholder Services Has Issued A Report Recommending A Vote Against A Director Candidate
Health Rounds: Veracyte genomic test identifies breast cancer patients who can skip chemo
Advisory: Alert wrongly tagged to Gold Rain Enterprises withdrawn